PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma

Acta Haematologica

Volumn 134, Issue 4, 2015, Pages 199-207

  Ercolak, Vehbi ^a   Paydas, Semra ^a   Bagir, Emine ^b   Ergin, Melek ^b   Seydaoglu, Gulsah ^a   Celik, Hikmet ^c   Yavuz, Basak ^c   Tanriverdi, Kahraman ^d   Gunaldi, Meral ^a   Afsar, Cigdem U ^a   Duman, Berna B ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b Sackler School of Medicine   (Turkey)

^c Toros Gene Biotechnology   (Turkey)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Disease free survival; Hodgkin's lymphoma; Immunohistochemistry; Overall survival; Preferentially expressed antigen of melanoma; Prognosis; Real time polymerase chain reaction

Indexed keywords

CANCER TESTIS ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; UNCLASSIFIED DRUG; PRAME PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84930514438     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000381533     Document Type: Article

References (34)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001.
2. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
3. Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP: Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 2007; 46: 796-804.
4. Yin B: PRAME: from diagnostic marker and tumor antigen to promising target of RNAi therapy in leukemic cells. Leuk Res 2011; 35: 1159-1160.
5. Payda S, Tanrverdi K, Yavuz S, Eydaolu G: PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res 2007; 31: 365-369.
6. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M: The tumor-associated antigen PRAME is universally expressed in highstage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10: 4307-4313.
7. Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C, Seliger B: Heterogenous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies Cancer Res 1998; 58: 4090-4095.
8. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G: Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 2008; 123: 2130-2137.
9. Bankovic J, Stojsic S, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic Z, Tanic N: Identification of genes associated with non-smallcell lung cancer promotion and progression. Lung Cancer 2010; 67: 151-159.
10. Figueiredo DL, Mameda RC, Proto-Siqueria R, Neder L, Silva WA Jr, Zago MA: Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 2006; 28: 614-619.
11. Haqq C, Nosrati M, Sudilovsky D: The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005; 102: 6092-6097.
12. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L: Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat 2008; 109: 359-365.
13. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R: PRAME expression and clinical outcome of breast cancer. Br J Cancer 2008; 99: 398-403.
14. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
15. Tan P, Zou C, Yong B, Han J, Zhang L, Su Q, Yin J, Wang J, Huang G, Peng T, Shen J: Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Commun 2012; 419: 801-808.
16. Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, Richter G, Mauz-Körholz C, Föll J, Körholz D: Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol 2008; 36: 886-896.
17. Costessi A, Mahrour N, Tijchon E, Stunnenberg R, Stoel MA, Jansen PW, Sela D, Martin-Brown S, Washburn MP, Florens L, Conaway JW, Conaway RC, Stunnenberg HG: The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J 2011; 30: 3786-3798.
18. Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Braüninger A, Hansmann ML: Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica 2006; 91: 596-604.
19. Payda S, Tanrverdi K, Yavuz S, Disel U, Balaml F, Burgut R: PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. J Hematol 2005; 79: 257-261.
20. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L: Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117.
21. McElwaine S, Mulligan C, Groet J, Spinelli M, Rinaldi A, Denyer G, Mensah A, Cavani S, Baldo C, Dagna-Bricarelli F, Hann I, Basso G, Cotter FE, Nizetic D: Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 2004; 125: 729-742.
22. Santamariá C, Chillón MC, Garciá-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Penãrrubia MJ, Giraldo P, San Miguel JF, Gonzalez M: The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica 2008; 93: 1797-1805.
23. Santamariá CM, Chillón MC, Garciá-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Penãrrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Diáz-Mediavilla J, San Miguel JF, Gonzalez M: Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia (CN-AML). Blood 2009; 114: 148-152.
24. Van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Colulie PG: PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells is expressed in acute leukemia cells. Br J Haematol 1998; 102: 1376-1379.
25. Matsushta M, Ikeda H, Kizaki M, Okamoto S, Osagawara M, Ikeda Y, Kawakami Y: Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukemia. Br J Haematol 2001; 112: 916-926.
26. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B: Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002; 133: 118-123.
27. Steinbach D, Viehmann S, Zintl F, Gruhn B: PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138: 89-91.
28. Proto-Siqueira R, Falcao RP, Souza CA, Ismael SJ, Zago MA: The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res 2003; 27: 393-396.
29. Van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, Andre M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielaemans K, Boon T: Genes encoding tumor-specific antigens are expressed in human myeloma cells Blood 1999; 94: 1156-1111.
30. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
31. Greiner J, Schmitt M: Cancer testis/germline antigens (CT/CG-antigens) in leukemias. Leuk Res 2007; 31: 1-3.
32. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M: Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28: 1413-1422.
33. Chambost H, Van Baren N, Brasseur F, Godelaine D, Xerri L, Landi SJ, Theate I, Plumas J, Spagnoli GC, Michel G, Coulie PG, Olive D: Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 2000; 95: 3530-3533.
34. Kawano R, Karube K, Kikuchi M, Takeshita M, Tamura K, Uike N, Eto T, Ohshima K, Suzumiya J: Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma. J Clin Exp Hematop 2009; 49: 1-7.